CDK4/6 Inhibitors: Game Changers in the Management of Hormone Receptor–Positive Advanced Breast Cancer?

Mirat Shah, Maria Raquel Nunes, Vered Stearns

Research output: Contribution to journalReview article

Abstract

The cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors palbociclib, ribociclib, and abemaciclib are rapidly transforming the care of patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (HR+/HER2-) advanced breast cancer. Current clinical questions include how to choose among these agents and how to sequence them with other therapies. Areas of active inquiry include identifying predictive biomarkers for CDK4/6 inhibitors, deciding whether to continue CDK4/6 inhibitors after disease progression, creating novel treatment combinations, and expanding use beyond HR+/HER2- advanced breast cancer. Here, we review the current use of and potential next directions for CDK4/6 inhibitors in the treatment of patients with HR+ breast cancer.

Original languageEnglish (US)
Pages (from-to)216-222
Number of pages7
JournalOncology (Williston Park, N.Y.)
Volume32
Issue number5
Publication statusPublished - May 15 2018

    Fingerprint

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this